Drug promotion and labeling in developing countries: an update.
Recent studies of drug promotion and labeling in Third World countries since 1972 have observed important changes in the policies of multinational corporations. Earlier studies found that multinational and national drug companies often grossly exaggerated the indications for the drugs and minimized or ignored the hazards. In the latest study, initiated in 1987, considerable improvement in promotional practices of the multinational corporations has been found, but little or no improvement on the part of the national companies. As a result, physicians are still provided with grossly exaggerated claims and the hazards of prescription drugs are covered up or glossed over. A very serious problem--the marketing of fraudulent drug products--has been identified in a number of Third World countries. Drug products are shaped and colored to resemble the original multinational company product, but contain only a small percentage of the active ingredient stated on the label, or perhaps none at all. In Indonesia fraudulent drug products may represent 20-30% of all drug products in the market. Similar fraudulent products have been reported in Brazil, Thailand, Bangladesh and Malaysia.
Lee
P R
PR
Institute for Health Policy Studies, University of California, San Francisco.
Lurie
P
P
Silverman
M M
MM
Lydecker
M
M
D003906:Developing Countries; D004345:Drug Industry; D004348:Drug Labeling; D005607:Fraud; D006801:Humans; D008389:Marketing of Health Services / Q000379:methods*; D014944:World Health Organization